Sankala Group
CYTK icon

Sankala Group’s Cytokinetics CYTK Stock Holding History

Sankala Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.3K Hold
201
– – 0.01% 352
2026
Q2 		$15.3K Hold
201
– – 0.01% 354
2026
Q1 		$12.8K Hold
201
– – 0.01% 348
2025
Q4 		$12.5K Buy
+201
New +$12.5K 0.01% 362

Other funds holding CYTK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Sankala Group's CYTK Position: Q3 2026 in Review

Sankala Group held its Cytokinetics (CYTK) position steady in Q3 2026 at 201 shares worth $13.3K. The position accounts for 0.01% of the portfolio, ranked #352.

Sankala Group first reported a position in CYTK in Q4 2025 and has held it in 4 quarters since. The position peaked at $15.3K in Q2 2026. 226 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • Sankala Group held 201 shares of Cytokinetics worth $13.3K as of Q3 2026.
  • Sankala Group left its Cytokinetics share count unchanged in Q3 2026.
  • Cytokinetics made up 0.01% of Sankala Group's portfolio in Q3 2026, its #352 holding.
  • Sankala Group first reported a position in Cytokinetics in Q4 2025 and has held it in 4 quarters since.
  • Sankala Group's Cytokinetics position peaked at $15.3K in Q2 2026.
  • 226 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.